FINWIRES · TerminalLIVE
FINWIRES

研究快讯:Kxs 第一季度:EBITDA 利润率高达 32%,远超预期,业绩双倍超出预期

By

-- 独立研究机构CFRA向提供了以下研究报告。CFRA分析师总结如下: KXS第一季度业绩表现强劲,营收达1.656亿美元(同比增长25%),远超预期;调整后每股收益为1.34美元,高于市场普遍预期的1.14美元,同比增长超过一倍。SaaS营收加速增长21%,达到1.029亿美元;订阅期限许可收入飙升111%;调整后EBITDA利润率意外提升700个基点,达到32%。强劲的业绩主要得益于创纪录的新业务订单、运营杠杆效应以及成功拿下大型客户项目和拓展现有客户关系。尽管第一季度业绩超出预期,管理层仍维持对2026财年的谨慎预期,预计营收为6.2亿美元至6.35亿美元,SaaS业务增长率为17%至19%。年度经常性收入加速增长20%,达到4.47亿美元;在轻资产模式下,经营现金流飙升87%,达到5910万美元。9.487亿美元的已签约收入储备提供了强劲的业绩可见性,预计2026年剩余时间内将实现3.093亿美元。我们认为维持目前的业绩指引较为保守,并相信公司能够超越这些目标。

Related Articles

Asia

StarHub's Net Attributable Profit Falls 81% in Q1

StarHub's (SGX:CC3) net attributable profit to shareholders plunged 81% in the first quarter of the year to SG$5.9 million from SG$31.8 million a year earlier, according to a Thursday filing with the Singapore Exchange.Revenue declined 6.1% year over year to SG$507.3 million from SG$540.5 million, mainly due to an across-the-board decline in services revenue.

$SGX:CC3
Asia

Meesho Narrows Consolidated Loss in Fiscal Q4

Meesho (NSE:MEESHO, BOM:544632) narrowed its consolidated attributable loss to 1.66 billion Indian rupees in the fiscal fourth quarter ended March 31, from a loss of 13.9 billion rupees a year ago.Loss per share contracted to 0.36 rupees from a loss per share of 3.39 rupees a year earlier, the online marketplace said in a filing to the Indian stock exchanges on Wednesday. The loss per share was lower than the 0.73 rupees estimated by the analysts polled by Visible Alpha.Revenue from operations in fiscal Q4 increased to 35.3 billion rupees from 24.0 billion rupees a year ago. This is a tad higher than Visible Alpha's estimate of 35.2 billion rupees a year ago.

$BOM:544632$NSE:MEESHO
Asia

Changchun High-Tech Gets Regulatory Nod for Gouty Arthritis Drug

Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Genescience Pharmaceutical obtained China's regulatory approval to manufacture and market its fuxinqibai monoclonal antibody injection.The drug is indicated for acute gouty arthritis attacks in adults poorly responsive to standard therapies, according to a Thursday filing with the Shenzhen bourse.

$SHE:000661